Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REGENXBIO Inc. (RGNX)
|
Add to portfolio |
|
|
|
| Price: |
$34.31
| | Metrics |
| OS: |
44.0
|
M
| |
-67
|
% ROE
|
| Market cap: |
$1.51
|
B
| |
-57
|
% ROIC
|
|
Net cash:
|
$68.6
|
M
| |
$1.56
|
per share
|
|
EV:
|
$1.44
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($286)
|
M
| |
|
|
| EPS |
($6.23)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 112.7 | 470.3 | 154.6 | 35.2 | 176.1 | 1.1 | 4.6 | 7.6 |
| Revenue growth | -76.0% | 204.3% | 338.7% | -80.0% | 16668.2% | -77.1% | -39.5% | 24.0% |
| Cost of goods sold | 54.5 | 51.8 | 35.7 | 8.2 | 9.6 | 1.7 | 1.0 | 1.5 |
| Gross profit | 58.2 | 418.5 | 118.9 | 27.0 | 166.4 | -0.7 | 3.6 | 6.1 |
| Gross margin | 51.6% | 89.0% | 76.9% | 76.6% | 94.5% | -62.8% | 79.1% | 80.2% |
| Selling, general and administrative | 321.1 | 258.5 | 238.1 | | | | | |
| Research and development | | | | 124.2 | 83.9 | 57.2 | 45.5 | 17.3 |
| General and administrative | | | | 51.8 | 36.9 | 27.2 | 23.6 | 11.9 |
| EBIT | -279.8 | 141.3 | -105.8 | -149.0 | 88.1 | -75.9 | -65.3 | -23.1 |
| EBIT margin | -248.2% | 30.0% | -68.5% | -422.9% | 50.0% | -7227.1% | -1423.8% | -304.9% |
| Pre-tax income | -280.4 | 141.2 | -106.0 | -97.5 | 104.1 | -73.2 | -63.4 | -22.8 |
| Income taxes | -0.1 | 13.4 | 5.2 | -2.8 | 4.2 | 0.0 | -0.4 | 0.0 |
| Tax rate | 0.0% | 9.5% | | 2.8% | 4.0% | 0.0% | 0.7% | 0.0% |
| Net income | -280.3 | 127.8 | -111.3 | -94.7 | 99.9 | -73.2 | -63.0 | -23.8 |
| Net margin | -248.7% | 27.2% | -72.0% | -268.9% | 56.8% | -6968.5% | -1372.1% | -313.6% |
| |
| Diluted EPS | ($6.50) | $2.91 | ($2.98) | ($2.58) | $2.73 | ($2.45) | ($2.38) | ($2.59) |
| Shares outstanding (diluted) | 43.2 | 43.9 | 37.3 | 36.7 | 36.6 | 29.9 | 26.4 | 9.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|